E
ET Healthcare
ET Healthcare is an in vitro diagnostic technology company
About ET Healthcare
ET Healthcare, established in 2008, operates in the in-vitro diagnostics market, providing automated immunoassay analyzers and reagents to clinical laboratories. The company was co-founded by Dr. Hong Tan, who serves as CEO, and Bob Zuk, the Chief Technology Officer. Dr. Tan brings entrepreneurial experience from founding a fiber optics company, Wave Crossing, and a bioscience firm, FortéBio, leveraging a background that includes work at Iomega and Seagate, and a PhD from Auburn University. Bob Zuk, with over 60 U.S. patents, contributes extensive experience in integrating biochemistry with device design from his time at companies like FortéBio and First Medical.
Headquartered in Palo Alto, California, with significant operations in Shanghai and Suzhou, China, the company targets the near-patient testing segment within hospitals and clinical labs. The business model centers on selling its proprietary diagnostic systems and the accompanying single-use, unitized test kits. This approach generates recurring revenue from the sale of consumables used with its analyzers. By offering cost-effective, unitized tests, the company also aims to minimize reagent waste, thereby reducing operational costs for laboratories.
The company's core product is the Pylon platform, which is based on its proprietary 'lab-on-a-tip' technology. This system is engineered for simplicity, featuring a plug-and-play setup with no fluidics, which simplifies maintenance. A key feature is the single-use Pylon Test Strip that contains all necessary reagents for a specific assay, capable of analyzing whole blood, plasma, and serum specimens. The platform provides a comprehensive testing portfolio for various critical conditions, including cardiac disease, inflammation, thrombosis, and hormonal disorders, delivering rapid and high-performance results.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES GOther financing | Apr 2021 | $105M | $420M | Qiming Venture Partners | — |
| SERIES COther financing | Sep 2018 | $18M | $70M | Maison Capital · Qiming Venture Partners | — |
Growth signals
Latest recorded traffic for ET Healthcare is 440 monthly website visits, down 39.7% over the last three months. ET Healthcare's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ET Healthcare in the Huangpu ecosystem
The ET Healthcare office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A2 investors entered at this stage
Series B and later1 investor entered at this stage
- MCMaison Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ET Healthcare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ET Healthcare’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











